

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Ischemia; reperfusion injury	Chemokine CX3C motif ligand 1 (CX3CL1; fractalkine)	Rodent studies suggest CX3CL1 could help decrease ischemia-induced tissue damage. In a mouse model of middle cerebral artery occlusion, intracerebroventricular injection of human CX3CL1 lowered ischemia-induced infarct volume compared with vehicle injection. In a rat model of cerebral ischemia, human CX3CL1 reduced infarct volume and improved functional outcomes compared with vehicle control. Next steps could include studying the effects of CX3CL1 administration after the ischemic insult.	Patent and licensing status unavailable	Cipriani, R. <i>et al. J. Neurosci.</i> ; published online Nov. 9, 2011; doi:10.1523/JNEUROSCI.3611-11.2011 Contact: Cristina Limatola, Sapienza University of Rome, Rome, Italy e-mail: cristina.limatola@uniroma1.it
		SciBX 4(46); doi:10.1038/scibx.2011.1296 Published online Dec. 1, 2011		